American Journal of Cardiology
Volume 103, Issue 11 , Pages 1592-1597, 1 June 2009

Relation of Immediate Decrease in Ventricular Septal Strain After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy to Long-Term Reduction in Left Ventricular Outflow Tract Pressure Gradient

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

Received 23 October 2008; received in revised form 31 January 2009; accepted 31 January 2009. published online 23 April 2009.

Alcohol septal ablation (ASA) aims to decrease left ventricular outflow tract (LVOT) obstruction in patients with obstructive hypertrophic cardiomyopathy (HC). To date, no diagnostic variables at baseline are available to predict long-term success of the procedure. We hypothesized that an immediate decrease in septal longitudinal strain after ASA would be associated with sustained LVOT gradient decrease after 6 months. ASA was performed in 22 patients with HC and severe drug-refractory symptoms. Clinical evaluation and 2-dimensional echocardiography were performed before, 1 day after, and 6 months after ASA. During 6-month follow-up, New York Heart Association class improved (2.7 ± 0.5 vs 1.4 ± 0.6, p <0.01) and LVOT gradient decreased (68 ± 31 vs 21 ± 21 mm Hg, p <0.01). Strain evaluation showed considerable decreases in basal septal strain (−12 ± 3% vs −8 ± 2%, p <0.01) and midseptal strain (−13 ± 4% vs −8 ± 3%, p <0.01) 1 day after ASA. Decreases in basal septal and midseptal strain 1 day after ASA were strongly related to the decrease in LVOT gradient during 6-month follow-up (r = 0.70, p <0.01, and r = 0.65, p <0.01, respectively). In conclusion, in patients with HC and severe drug-refractory symptoms, immediate decrease in septal strain after ASA is strongly related to a decrease in LVOT gradient after 6 months and might therefore serve as an early determinant for long-term success of the ASA procedure.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Bax received supporting grants from Medtronic, Boston Scientific, BMS Medical Imaging, St. Jude Medical, Edwards Lifesciences, and GE Healthcare.

PII: S0002-9149(09)00548-7

doi:10.1016/j.amjcard.2009.01.373

American Journal of Cardiology
Volume 103, Issue 11 , Pages 1592-1597, 1 June 2009